Climb Bio enters licensing deal with Mabworks for CLYM116 development
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...
Contract Pharma1h
Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine
Agreement grants Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet ...
Cargo Therapeutics, Inc.: CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...
manilatimes4h
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...
Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
manilatimes18h
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...